Virtual Reality-Based Attention Bias Modification Training for Adolescents With Anorexia Nervosa (AN-VR-ABMT)

January 14, 2026 updated by: Jose Gutierrez Maldonado, University of Barcelona

AN-VR-ABM: Attentional Bias Modification and Body Exposure Using Virtual Reality and Eye-Tracking to Enhance Treatment for Adolescents With Anorexia Nervosa

Anorexia Nervosa (AN) is considered one of the most severe subtypes of eating disorders (EDs), characterized by significant medical complications, high mortality rates, and high comorbidity with other disorders, such as anxiety disorders. Similarly to what occurs in anxiety disorders, several studies have suggested the presence of dysfunctional body-related attentional bias (AB) in patients with EDs, and specifically in patients with AN. Individuals with AN tend to focus their attention on their body in a dysfunctional manner, engaging in body-checking behaviors and excessively scrutinizing their general appearance and weight-related body parts. This body-related AB has been associated with higher levels of body dissatisfaction, which represents one of the most important risk factors for the development and maintenance of EDs.

Moreover, body-related AB may contribute to reducing the effectiveness of body exposure-based treatments used in patients with AN. For this reason, it is necessary to develop new treatment techniques by incorporating specific components aimed at reducing body-related AB. It has been proposed that attentional bias modification techniques could be integrated into body exposure therapy as an effective approach to reduce body-related AB, body dissatisfaction, and body anxiety.

To date, our research group has been the first to use a combination of virtual reality (VR) and eye-tracking (ET) technologies to assess the presence of body-related AB in non-clinical samples. In order to improve treatments for AN, the present project aims to develop a novel attentional bias modification procedure using ET and VR technologies. In addition, this project seeks to integrate this AB modification procedure into a body exposure-based treatment designed to reduce the fear of weight gain experienced by patients with AN.

Finally, the project aims to evaluate whether combining two distinct components-body exposure-based therapy and attentional bias modification training-results in a more effective intervention. It is expected that the inclusion of a VR-based body exposure procedure in standard AN treatment, enhanced through the illusion of ownership over a virtual body, will lead to improved treatment outcomes. Furthermore, it is anticipated that the addition of attentional bias modification training to the body exposure-based procedure will further enhance treatment effectiveness.

Study Overview

Detailed Description

Attentional bias (AB) refers to the tendency to allocate greater attention to certain types of stimuli or information (e.g., disorder-relevant information) over other types of information. Adolescent patients with Anorexia Nervosa (AN) have been shown to focus more on self-perceived unattractive body parts than on other body parts. Dysfunctional body-related AB is thought to maintain body image disturbances commonly reported by adolescents with AN by selectively processing body-related information that is consistent with dysfunctional cognitive schemas (e.g., "I am getting a fatter belly"), while schema-inconsistent information (e.g., "I am getting thinner") receives less attention and is often visually neglected.

Dysfunctional body-related AB may also contribute to the reduced effectiveness of body exposure-based treatments for adolescents with AN. Therefore, there is a need to develop novel treatment approaches by incorporating specific components aimed at reducing body-related AB in this population. In a previous project conducted by our group, preliminary evidence supported the effectiveness of body-related AB modification in adolescent patients with AN following a virtual reality (VR)-based mirror exposure intervention. A key factor underlying these results may lie in the structure of the procedure, in which patients were required to sequentially focus on different parts of a virtual body (from head to feet) and verbally express their thoughts and emotions related to each body area.

Building on these findings, the present project aims to further advance this line of research by integrating attentional bias modification techniques into body exposure therapy as an effective approach to reducing body-related AB, body dissatisfaction, and body anxiety in adolescents with AN. To date, our research group has been among the first to combine virtual reality (VR) and eye-tracking (ET) technologies to assess body-related AB in both clinical and non-clinical samples. Specifically, this project seeks to determine whether the addition of attentional bias modification training to body exposure-based therapy results in a more effective intervention for adolescents diagnosed with AN.

It is hypothesized that incorporating AB modification training into the body exposure-based procedure (experimental group) will lead to greater treatment efficacy compared with treatment as usual (control group). Specifically, adolescents in the experimental group are expected to show a significant increase in body mass index (BMI) and a significant reduction in core AN symptomatology (e.g., fear of weight gain, body image disturbances), as well as a reduction in body-related AB, from pre- to post-treatment, compared with the control group. These improvements are also expected to be maintained at the six-month follow-up.

The project will be conducted at the Eating Disorders Units of Hospital Sant Joan de Déu (Barcelona, Spain), which specializes in the treatment of adolescents with eating disorders.

Adolescent patients with AN will be exposed to an immersive virtual environment using a VR head-mounted display (HTC Pro Eye) equipped with integrated eye-tracking. In addition to the two controllers typically provided with the HTC Pro Eye system, three additional body trackers will be used to enable full-body motion tracking. The virtual environment will consist of a room featuring a large mirror positioned on the front wall, approximately 1.5 m in front of the participant, and large enough to reflect the entire body. A young female avatar wearing a basic white T-shirt, blue jeans, and black trainers will be created for the intervention.

Regarding the treatment protocol, all sessions will last approximately one hour and will be conducted once per week. Each session will begin with the induction of the full-body illusion (FBI) and the assessment of visual analogue scales (VASs). Body exposure will initially involve a virtual body with the same BMI as the adolescent patient. The attentional bias modification training will be based on an adaptation of the AB induction procedure proposed by Smeets, Jansen, and Roefs (2011). The training will involve the visual selection of geometric figures (e.g., squares, rectangles, circles) that approximately correspond to specific body parts, with each figure presented in different colors. Participants will be required to detect and identify figures appearing on different parts of the avatar's body. In 50% of the trials, discrimination will be based on shape, while in the remaining 50% it will be based on color. Throughout the training, figures will appear on weight-related body parts in 45% of the trials and on non-weight-related body parts in another 45% of the trials. In the remaining 10% of trials, figures will appear on one of three neutral stimuli positioned next to the avatar.

Raw eye-tracking data will be processed using Ogama (Open Gaze and Mouse Analyzer) software to obtain quantitative measures of visual attention. Weight-related and non-weight-related areas of interest (AOIs) will be defined a priori. Weight-related AOIs will be determined based on the weight-related body items of the PASTAS questionnaire and mapped onto a frontal-view image of a female avatar. These weight-related AOIs will include the legs, thighs, buttocks, hips, abdomen, and waist. All remaining body parts (head, neck, chest, shoulders, arms, and feet) will be classified as non-weight-related AOIs. Selective visual attention will be assessed using total fixation duration and the number of fixations within each AOI.

Study Type

Interventional

Enrollment (Actual)

75

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Barcelona
      • Barcelona, Barcelona, Spain, 08950
        • Hospital Sant Joan de Déu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

10 years and older (Child)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Female adolescents aged 12-17 years.
  • Primary diagnosis of anorexia nervosa according to DSM-5 criteria.
  • Body weight below the expected range for height, age, and sex.
  • Ability to understand and communicate in Spanish.

Exclusion Criteria:

  • Presence of severe mental disorders other than anorexia nervosa.
  • Significant cognitive impairment that would interfere with participation.
  • Visual or auditory deficits that could interfere with VR-based body exposure therapy.
  • Epilepsy.
  • Pregnancy.
  • Cardiac arrhythmia.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Treatment as usual + VR-based body + Attentional Bias Modification Training.
In this group, five sessions of VR-based body exposure will be added to the usual treatment, as in the other experimental group. Additionally, at the beginning of each exposure session, participants will undergo attentional bias modification training. The training involves the visual selection of geometric figures that approximately correspond to specific body parts, with each figure presented in different colors. Participants must detect and identify figures appearing on different parts of the avatar's body. In 50% of the trials, discrimination will be based on shape, and in the remaining 50%, it will be based on color. Throughout the training, figures will appear on weight-related body parts in 45% of the trials, on non-weight-related body parts in another 45% of the trials, and on one of three neutral stimuli located next to the avatar in the remaining 10% of trials.
Combine usual treatment with an additional five VR-based body-exposure therapy sessions and five sessions of Attentional Bias Modification Training.
Combine the usual treatment with an additional five VR-based body-exposure therapy sessions

Participants were recruited from the day-patient and home-treatment programs of the eating disorders unit.

The day-patient program followed a cognitive-behavioral therapy model and included nutritional rehabilitation, behavioral strategies for improving eating and weight gain, individual and group psychotherapy, and parental support. Attendance ranged from 6 to 11 hours per day, depending on patient risk. The home-treatment program served as transitional care between hospitalization and outpatient treatment and focused on medical stabilization, weight restoration, family involvement, psychoeducation, emotional regulation, and social skills development. Both cognitive-behavioral therapy and family-based therapy were delivered either in person or remotely. Standard treatment procedures for eating disorders were applied across all groups.

Experimental: Treatment as usual + VR-based body exposure
Patients assigned to this group will receive the usual treatment provided by their clinical unit, in addition to five weekly sessions of a VR-based body exposure intervention. During these sessions, participants will undergo body exposure using a virtual avatar representing their actual body measurements. The avatar's BMI will be progressively increased across sessions until a healthy BMI is reached.
Combine the usual treatment with an additional five VR-based body-exposure therapy sessions

Participants were recruited from the day-patient and home-treatment programs of the eating disorders unit.

The day-patient program followed a cognitive-behavioral therapy model and included nutritional rehabilitation, behavioral strategies for improving eating and weight gain, individual and group psychotherapy, and parental support. Attendance ranged from 6 to 11 hours per day, depending on patient risk. The home-treatment program served as transitional care between hospitalization and outpatient treatment and focused on medical stabilization, weight restoration, family involvement, psychoeducation, emotional regulation, and social skills development. Both cognitive-behavioral therapy and family-based therapy were delivered either in person or remotely. Standard treatment procedures for eating disorders were applied across all groups.

Active Comparator: Treatment as usual
Patients assigned to this group will receive the usual treatment from the center where they are recruited for the study and will be required to complete the evaluations according to the same schedule as the experimental group.

Participants were recruited from the day-patient and home-treatment programs of the eating disorders unit.

The day-patient program followed a cognitive-behavioral therapy model and included nutritional rehabilitation, behavioral strategies for improving eating and weight gain, individual and group psychotherapy, and parental support. Attendance ranged from 6 to 11 hours per day, depending on patient risk. The home-treatment program served as transitional care between hospitalization and outpatient treatment and focused on medical stabilization, weight restoration, family involvement, psychoeducation, emotional regulation, and social skills development. Both cognitive-behavioral therapy and family-based therapy were delivered either in person or remotely. Standard treatment procedures for eating disorders were applied across all groups.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Drive for Thinness (EDI-DT)
Time Frame: Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Change in drive for thinness scores as measured by the Eating Disorder Inventory-3 - drive for thinness (EDI-DT) scale. Scores range from 0 to 28, with higher scores indicating greater drive for thinness.
Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Change in Body Dissatisfaction (EDI-BD)
Time Frame: Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Change in body dissatisfaction scores as measured by the Eating Disorder Inventory-3 - body dissatisfaction (EDI-BD) scale. Scores range from 0 to 40, with higher scores indicating greater body dissatisfaction.
Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Change in Body Dissatisfaction (BIAS - BD)
Time Frame: Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Body dissatisfaction scores were assessed using the Figural Drawing Scale for Body Image Assessment (BIAS-BD). Scores range from -80 to 80, with higher absolute values indicating greater body dissatisfaction.
Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Change in Body Distortion (BIAS - BD)
Time Frame: Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Body distortion scores were assessed using the Figural Drawing Scale for Body Image Assessment (BIAS-BD). Scores range from -80 to 80, with higher absolute values indicating greater body distortion.
Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Change in complete fixation time towards weight-related body parts
Time Frame: Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Change in attentional bias towards weight-related body parts, measured as the total fixation time of gaze (evaluated in milliseconds). Higher values indicate greater attentional bias.
Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Change in the number of fixations towards weight-related body parts
Time Frame: Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Change in attentional bias towards weight-related body parts, measured as the number of fixations of gaze. Higher values indicate greater attentional bias.
Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Change in Body Mass Index values
Time Frame: Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Change in Body Mass Index was calculated as weight (kg) divided by height (m) squared. Higher values indicate greater BMI.
Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Change in Fear of Gaining Weight
Time Frame: Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Change in fear of gaining weight, measured using a visual analogue scale (0-100). Higher scores indicate greater fear of gaining weight.
Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Change in Anxiety
Time Frame: Assessed at baseline (before the body exposure session); every 2 minutes during the exposure session; at the end of the exposure session; at the end of treatment (6 weeks); and at 6-month follow-up.
Change in anxiety, measured using a visual analogue scale (0-100). Higher scores indicate greater anxiety.
Assessed at baseline (before the body exposure session); every 2 minutes during the exposure session; at the end of the exposure session; at the end of treatment (6 weeks); and at 6-month follow-up.
Change in Body-related Anxiety (PASTAS)
Time Frame: Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Change in body-related anxiety as measured by the Physical Appearance State Anxiety Scale (PASTAS). Total scores range from 0 to 32, with higher scores indicating greater body-related anxiety.
Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Change in Body Appreciation (BAS)
Time Frame: Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.
Change in body appreciation as measured by the Body Appreciation Scale (BAS), with scores ranging from 13 to 65; higher scores indicate greater body appreciation.
Assessed at baseline, at the end of treatment (6 weeks), and at 6-month follow-up.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in number of fixations of the gaze towards weight-related body parts
Time Frame: From pre-assessment to post-assessment after 6 weeks
Evaluation of the attentional bias towards the body using complete fixation time (evaluated in milliseconds) of the gaze towards weight-related body parts, with higher values indicating a greater attentional bias.
From pre-assessment to post-assessment after 6 weeks
Change in complete fixation time of the gaze towards weight-related body parts
Time Frame: From pre-assessment to post-assessment after 6 weeks .
Evaluation of the attentional bias towards the body using number of fixations of the gaze towards weight-related body parts, with higher values indicating a greater attentional bias
From pre-assessment to post-assessment after 6 weeks .
Change in complete fixation time of the gaze towards weight-related body parts
Time Frame: From pre-assessment to post-assessment after 6 weeks , and at the six-month follow-up
Evaluation of the attentional bias towards the body using number of fixations of the gaze towards weight-related body parts, with higher values indicating a greater attentional bias
From pre-assessment to post-assessment after 6 weeks , and at the six-month follow-up
Figural Drawing Scale for Body Image Assessment (BIAS-BD) body distortion scores
Time Frame: From pre-assessment to post-assessment after 6 weeks , and at the six-month follow-up
Evaluation of the change in body distortion using the BIAS-BD body distortion scores, ranging from -80 to 80, with higher scores indicating higher body distortion
From pre-assessment to post-assessment after 6 weeks , and at the six-month follow-up
Figural Drawing Scale for Body Image Assessment (BIAS-BD) body dissatisfaction scores
Time Frame: From pre-assessment to post-assessment after 6 weeks , and at the six-month follow-up
Evaluation of the change in body dissatisfaction using the BIAS-BD body distortion scores, ranging from -80 to 80, with higher scores indicating higher body distortion
From pre-assessment to post-assessment after 6 weeks , and at the six-month follow-up
Change in Physical Appearance State Anxiety Scale (PASTAS)
Time Frame: From pre-assessment to post-assessment after 6 weeks , and at the six-month follow-up
Evaluation of body-related anxiety using the PASTAS, with a maximum score of 32, with higher scores indicating higher body-related anxiety
From pre-assessment to post-assessment after 6 weeks , and at the six-month follow-up
Change in Body Appreciation Scale (BAS)
Time Frame: From pre-assessment to post-assessment after 6 weeks , and at the six-month follow-up
Evaluation of the change in body appreciation using the BAS, with a scale of possible scores ranging from 13-65, where higher scores indicate higher body appreciation
From pre-assessment to post-assessment after 6 weeks , and at the six-month follow-up

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body-related anxiety
Time Frame: Up to 40 minutes. Baseline (prior to beginning the body exposure session), every two minutes during the exposure, and at the end of the body exposure session
Visual analogue scale from 0 to 100, with higher scores indicating higher body-related anxiety
Up to 40 minutes. Baseline (prior to beginning the body exposure session), every two minutes during the exposure, and at the end of the body exposure session
Fear of gaining weight
Time Frame: Up to 40 minutes. Baseline (prior to beginning the body exposure session) and at the end of the body exposure session ]
Visual analogue scale from 0 to 100, with higher scores indicating higher fear of gaining weight
Up to 40 minutes. Baseline (prior to beginning the body exposure session) and at the end of the body exposure session ]

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: José Gutiérrez-Maldonado, jgutierrezm@ub.edu

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 21, 2021

Primary Completion (Actual)

February 2, 2023

Study Completion (Actual)

February 29, 2024

Study Registration Dates

First Submitted

February 25, 2021

First Submitted That Met QC Criteria

March 3, 2021

First Posted (Actual)

March 8, 2021

Study Record Updates

Last Update Posted (Estimated)

January 16, 2026

Last Update Submitted That Met QC Criteria

January 14, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The data presented in this study will be available on request from the corresponding author. The data are not publicly available due to patients' privacy restrictions.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anorexia Nervosa

Clinical Trials on Attentional Bias Modification Training

Subscribe